Chromium-Insulin Complex for Stable Glucose Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing blood glucose levels in diabetes patients, particularly Type 1 and Type 2 diabetics, are prone to causing hypoglycemia due to the difficulty in accurately administering insulin, leading to severe health complications such as seizures, brain damage, and death, and there is a need for safer and more optimal insulin administration methods.
Innovation Solution
A chromium-insulin complex is developed, where chromium is combined with insulin in non-stoichiometric amounts to form a molecular weight between 30 and 40 kDa, enhancing insulin absorption and glucose regulation, thereby stabilizing serum glucose levels and reducing weight-related issues associated with insulin therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin is administered to manage blood glucose levels in diabetes patients, then glucose regulation is improved, but the risk of hypoglycemia increases
Solution Approach 1:
Chromium serves as an intermediary substance that modulates insulin's action on glucose metabolism. The chromium-insulin complex allows chromium to mediate between insulin administration and glucose regulation, enhancing insulin's effectiveness while reducing the severity of hypoglycemic episodes through chromium's independent glucose-metabolizing properties
Solution Approach 2:
The invention creates a composite therapeutic agent by combining insulin and chromium into a unified treatment protocol. This composite approach integrates two substances with complementary mechanisms: insulin for direct glucose uptake and chromium for enhanced insulin sensitivity and alternative glucose metabolism pathways, thereby achieving more reliable glucose control with reduced hypoglycemia risk
2Reliability
If insulin is administered to control blood glucose, then diabetes treatment effectiveness is improved, but severe health complications such as seizures, brain damage, and death may occur
Solution Approach 1:
Chromium provides preliminary protective action against the harmful effects of insulin-induced hypoglycemia. By co-administering chromium, the system pre-establishes protective mechanisms including alternative glucose metabolism pathways and enhanced neuronal glucose uptake independence, which prevent severe complications before they occur
Solution Approach 2:
The invention converts the potentially harmful effect of insulin-induced hypoglycemia into a beneficial outcome by utilizing chromium's ability to stimulate alternative glucose metabolism pathways. The harmful hypoglycemic state is transformed into an opportunity for chromium-mediated glucose normalization through non-insulin pathways, thereby preventing severe complications while maintaining treatment effectiveness
3Reliability
If insulin therapy is used to manage diabetes, then glucose levels are controlled, but weight-related complications arise
Solution Approach 1:
Chromium induces parameter changes in glucose metabolism by enhancing insulin sensitivity and stimulating alternative metabolic pathways. This changes the metabolic parameters from insulin-dependent glucose uptake to a dual-pathway system involving both insulin-mediated and chromium-stimulated glucose metabolism, thereby controlling glucose levels while preventing the weight gain associated with pure insulin therapy
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A composition comprising chromium and insulin and/or a chromium-insulin complex, its method of preparation, and its use in the prevention and treatment of hypoglycemia and hypoglycemia-related conditions. This composition can be administered in numerous ways, including parenterally, intranasally, and orally. The composition stabilizes serum glucose levels and has a synergistic effect compared to chromium and insulin administered separately.